2 weeks Ago By Defense World Staff
Mizuho started coverage on shares of Tectonic Therapeutic (NASDAQ:TECX – Free Report) in a research note issued to investors on Monday, Marketbeat reports. The brokerage issued an outperform rating and a $51.00 price target on the stock.
Separately, Wells Fargo & Company reduced their target price on shares of Tectonic Therapeutic from $112.00 to $101.00 and set an “overweight” rating on the stock in a research note on Friday, March 21st.
Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Tectonic Therapeutic presently has an average rating of “Buy” and a consensus price target of $72.
40.Check Out Our Latest Analysis on Tectonic TherapeuticTectonic Therapeutic Price PerformanceNASDAQ:TECX opened at $17.92 on Monday.
The company has a market cap of $334.44 million, a price-to-earnings ratio of -3.04 and a beta of 2.
87. Tectonic Therapeutic has a 1 year low of $13.70 and a 1 year high of $61.
07. The stock’s 50 day simple moving average is $22.13 and its two-hundred day simple moving average is $35.
60. Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.
84) earnings per share for the quarter, topping the consensus estimate of ($1.39) by $0.55.
As a group, analysts anticipate that Tectonic Therapeutic will post -8.31 EPS for the current year. Insider Buying and Selling at Tectonic TherapeuticIn related news, CFO Daniel Lochner acquired 4,617 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th.
The stock was bought at an average price of $54.14 per share, for a total transaction of $249,964.38.
Following the acquisition, the chief financial officer now directly owns 4,617 shares of the company’s stock, valued at $249,964.38. This represents a ∞ increase in their position.
The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Timothy A. Springer bought 3,718 shares of the company’s stock in a transaction on Wednesday, April 9th.
The stock was bought at an average price of $14.76 per share, for a total transaction of $54,877.68.
Following the completion of the purchase, the director now directly owns 4,317,276 shares in the company, valued at approximately $63,722,993.76. This represents a 0.
09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 234,607 shares of company stock valued at $8,955,655 in the last quarter.
9.20% of the stock is owned by insiders. Institutional Inflows and OutflowsSeveral institutional investors have recently bought and sold shares of TECX.
JPMorgan Chase & Co. lifted its holdings in shares of Tectonic Therapeutic by 5,554.5% in the 4th quarter.
JPMorgan Chase & Co. now owns 1,244 shares of the company’s stock worth $57,000 after buying an additional 1,222 shares during the period. Virtus ETF Advisers LLC purchased a new stake in Tectonic Therapeutic in the fourth quarter worth about $71,000.
China Universal Asset Management Co. Ltd. purchased a new stake in Tectonic Therapeutic in the fourth quarter worth about $144,000.
Charles Schwab Investment Management Inc. bought a new position in Tectonic Therapeutic during the 4th quarter worth about $218,000. Finally, Raymond James Financial Inc.
purchased a new position in Tectonic Therapeutic during the 4th quarter valued at about $228,000. 62.63% of the stock is currently owned by hedge funds and other institutional investors.
Tectonic Therapeutic Company Profile (Get Free Report)Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Featured ArticlesFive stocks we like better than Tectonic TherapeuticStock Average Calculator AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockAbout the Markup CalculatorWhy Call Option Traders Are Targeting This Dividend ETF Now3 Dividend Kings To ConsiderIs Alphabet Misunderstood? Here’s Why the Bulls Are Buying.
